From the 1Department of Public Health, Texas Tech University Health Sciences Center, Lubbock, TX
2Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN
3Department of Biostatistics, The Ohio State University, Columbus OH
4Department of Cardiology, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
5Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MA
6Department of Medicine, Baylor College of Medicine. Houston, TX.
Received November 16, 2021; revised and accepted April 4, 2022.
Funding/support: The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under contract nos. (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, HHSN268201700005I). D.A. was supported by the National Heart, Lung, and Blood Institute Research Supplement HHSN268201700003I/75N92019F00075. SomaLogic conducted the SOMAscan assays in exchange for use of Atherosclerosis Risk in Communities data. This work was supported in part by NIH/NHLBI grant R01 HL134320.
Financial disclosure/conflicts of interest: E.D.M. reports advisory boards: Amarin, AstraZeneca, Bayer, Esperion, Novartis, Novo Nordisk. The other authors have nothing to declare.
Supplemental digital content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal’s Website (www.menopause.org).
Address correspondence to: Duke Appiah, PhD, MPH, Department of Public Health, Texas Tech University Health Sciences Center, 3601 4th St, STOP 9430. Lubbock, TX 79430. E-mail: [email protected]
